Skip to Content

METANIUM NAPPY RASH OINTMENT

Active substance(s): TITANIUM DIOXIDE / TITANIUM PEROXIDE / TITANIUM SALICYLATE / TITANIUM DIOXIDE / TITANIUM PEROXIDE / TITANIUM SALICYLATE / TITANIUM DIOXIDE / TITANIUM PEROXIDE / TITANIUM SALICYLATE

View full screen / Print PDF » Download PDF ⇩

PDF Transcript

SUMMARY OF PRODUCT CHARACTERISTICS

1

NAME OF THE MEDICINAL PRODUCT
Metanium Nappy Rash Ointment

2

QUALITATIVE AND QUANTITATIVE COMPOSITION
Titanium Dioxide
Titanium Peroxide
Titanium Salicylate

3

20.0% w/w
5.0% w/w
3.0% w/w

PHARMACEUTICAL FORM
Ointment for topical administration.

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
As a treatment for nappy rash

4.2

Posology and method of administration

Posology:
Topical.
Adults:
Not applicable.
Elderly:
Not applicable.

Children:
Dab a small amount of Metanium over the sore area. Spread the ointment
thinly so the skin texture can be clearly seen through it. Repeat at each nappy
change.

4.3

Contraindications
Hypersensitivity to the drug formulation.

4.4

Special warnings and precautions for use
If no response occurs, or the condition worsens, consult your doctor.
For external use only.

4.5

Interaction with other medicinal products and other forms of interaction
Not known.

4.6

Pregnancy and lactation
Not known.

4.7

Effects on ability to drive and use machines
Not applicable.

4.8

Undesirable effects

Rarely: skin irritations.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal
product is important. It allows continued monitoring of the benefit/risk balance
of the medicinal product. Healthcare professionals are asked to report any
suspected adverse reactions via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard.
4.9

Overdose
Overdose is unlikely when Metanium Nappy Rash Ointment is used as instructed for
treating nappy rash. However, as this product contains titanium salicylate, accidental
ingestion or excessive topical application could lead to symptoms of salicylate
poisoning.
Salicylate poisoning is usually associated with plasma concentrations >350 mg/L (2.5
mmol/L). Most adult deaths occur in patients whose concentrations exceed 700 mg/L
(5.1 mmol/L). Single doses less than 100 mg/kg are unlikely to cause serious
poisoning.
Symptoms
Common features include vomiting, dehydration, tinnitus, vertigo, deafness,
sweating, warm extremities with bounding pulses, increased respiratory rate and
hyperventilation. Some degree of acid-base disturbance is present in most cases. A
mixed respiratory alkalosis and metabolic acidosis with normal or high arterial pH
(normal or reduced hydrogen ion concentration) is usual in adults and children over
the age of four years. In children aged four years or less, a dominant metabolic
acidosis with low arterial pH (raised hydrogen ion concentration) is common.
Acidosis may increase salicylate transfer across the blood brain barrier. Uncommon
features include haematemesis, hyperpyrexia, hypoglycaemia, hypokalaemia,
thrombocytopaenia, increased INR/PTR, intravascular coagulation, renal failure and
non-cardiac pulmonary oedema. Central nervous system features including confusion,
disorientation, coma and convulsions are less common in adults than in children.
Management
Give activated charcoal if an adult presents within one hour of ingestion of more than
250 mg/kg. The plasma salicylate concentration should be measured, although the
severity of poisoning cannot be determined from this alone and the clinical and
biochemical features must be taken into account. Elimination is increased by urinary
alkalinisation, which is achieved by the administration of 1.26% sodium bicarbonate.
The urine pH should be monitored. Correct metabolic acidosis with intravenous 8.4%
sodium bicarbonate (first check serum potassium). Forced diuresis should not be used
since it does not enhance salicylate excretion and may cause pulmonary oedema.
Haemodialysis is the treatment of choice for severe poisoning and should be
considered in patients with plasma salicylate concentrations >700 mg/L (5.1
mmol/L), or lower concentrations associated with severe clinical or metabolic
features. Patients under ten years or over 70 have increased risk of salicylate toxicity
and may require dialysis at an earlier stage.

5

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties
The combination of titanium salts with a water repellent siliconised base forms
a tenacious non-occlusive film on the skin which protects against irritation and
repeated hydration.

5.2

Pharmacokinetic properties
Metanium is indicated for topical use and has an action similar to zinc oxide
preparations.

5.3

Preclinical safety data
Not applicable.

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients
Dimethicone 350
Light Liquid Paraffin
Tincture of Benzoin
White Soft Paraffin.

6.2

Incompatibilities
Not known.

6.3

Shelf life
36 months.

6.4

Special precautions for storage
Do not store above 25°C.

6.5

Nature and contents of container
Aluminium collapsible tube with membrane seal and spiked polypropylene
cap.
Pack sizes: 25 g, 30 g.

6.6

Special precautions for disposal
No special precautions necessary.

7

MARKETING AUTHORISATION HOLDER

Thornton & Ross Ltd
Linthwaite
Huddersfield
HD7 5QH
United Kingdom

8

MARKETING AUTHORISATION NUMBER(S)
PL 00240/0366

9

DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
30/04/02.

10

DATE OF REVISION OF THE TEXT
18/02/2015

Expand Transcript

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide